CFO Capital Management’s GSK GSK Stock Holding History

CFO Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$315K	Hold	5,816	–	–	0.26%	83
2025 Q4	$285K	Buy	+5,816	New	+$271K	0.21%	93

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CFO Capital Management's GSK Position: Q1 2026 in Review

CFO Capital Management held its GSK (GSK) position steady in Q1 2026 at 5,816 shares worth $315K. The position accounts for 0.26% of the portfolio, ranked #83.

CFO Capital Management first reported a position in GSK in Q4 2025 and has held it in 2 quarters since. 1,034 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

CFO Capital Management held 5,816 shares of GSK worth $315K as of Q1 2026.
CFO Capital Management left its GSK share count unchanged in Q1 2026.
GSK made up 0.26% of CFO Capital Management's portfolio in Q1 2026, its #83 holding.
CFO Capital Management first reported a position in GSK in Q4 2025 and has held it in 2 quarters since.
1,034 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on CFO Capital Management's 13F filing for Q1 2026, filed 4 May 2026.